Unum Therapeutics Inc (UMRX) Given Average Rating of “Buy” by Brokerages
Shares of Unum Therapeutics Inc (NASDAQ:UMRX) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $14.60.
UMRX has been the topic of a number of research reports. Zacks Investment Research cut Unum Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. Cowen initiated coverage on Unum Therapeutics in a research report on Tuesday, February 26th. They set a “market perform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Unum Therapeutics in a research report on Friday, March 29th. Finally, SunTrust Banks dropped their price target on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a research report on Friday, March 29th. They noted that the move was a valuation call.
In related news, insider Seth Ettenberg sold 11,485 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $4.12, for a total value of $47,318.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Unum Therapeutics stock opened at $3.31 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.65 and a current ratio of 2.65. The company has a market cap of $103.31 million, a PE ratio of -2.38 and a beta of 2.25. Unum Therapeutics has a twelve month low of $3.03 and a twelve month high of $17.66.
Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.15 million. Unum Therapeutics had a negative return on equity of 62.24% and a negative net margin of 373.81%. As a group, research analysts expect that Unum Therapeutics will post -1.35 EPS for the current year.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
See Also: Support Level
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.